• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Researchers reverse diabetes in mice by infusing them with blood stem cells

November 17, 2017 By Sarah Faulkner

BCH diabetes cell therapyResearchers at Boston Children’s Hospital successfully reversed Type I diabetes in a mouse model using blood stem cells, according to a study published this week in Science Translational Medicine.

The researchers used cells that were pre-treated to make more of a protein, PD-L1, which is deficient in mice and people with Type I diabetes.

“There’s really a reshaping of the immune system when you inject these cells,” senior investigator Dr. Paolo Fiorina said in prepared remarks.

Researchers have tried before to use immunotherapies in an attempt to stop the body’s attack on its own islet cells. Efforts to reboot a patient’s immune system by infusing them with their own blood stem cells has helped some patients, but not all of them.

The team at Boston Children’s Hospital said that previous attempts have failed because the therapies do not specifically target diabetes.

“Blood stem cells have immune-regulatory abilities, but it appears that in mice and humans with diabetes, these abilities are impaired,” Fiorina explained. “We found that in diabetes, blood stem cells are defective, promoting inflammation and possibly leading to the onset of disease.”

The team discovered that the genetic regulatory factors responsible for production of PD-L1 are different in blood stem cells from diabetic mice and people, which ultimately stops the production of PD-L1.

PD-L1 binds to the PD-1 receptor on inflammatory T-cells that are triggered to cause autoimmune reactions, the researchers found. When PD-L1 binds to the PD-1 receptor, the T-cells die or become inactive.

The team reported that when they added a healthy gene for PD-L1 into the blood stem cells, the cells reversed diabetes in the mouse model.

They also achieved the same results by treating the cells with a mix of three small molecules.

“We think resolution of PD-L1 deficiency may provide a novel therapeutic tool for the disease,” first author Moufida Ben Nasr said.

The researchers have teamed up with San Diego, Calif.-based Fate Therapeutics to optimize the small-molecule cocktail used to treat the blood stem cells before infusion. They have met with the FDA for a pre-IND meeting in preparation for a clinical trial in patients with Type I diabetes, the team reported.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Diabetes, Featured, Pharmaceuticals, Regenerative Medicine, Research & Development, Stem Cells Tagged With: Boston Children's Hospital

IN CASE YOU MISSED IT

  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development
  • Ypsomed brings autoinjector for dual GCG/GLP-1 delivery to China
  • Convatec wins FDA approval for Parkinson’s treatment infusion tech

Reader Interactions

Comments

  1. Operon Strategist says

    August 11, 2018 at 5:26 am

    Thank you for sharing this article with us. Hopefully with this a cure for diabetes look imminent.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS